10-Q: Elevai Labs Inc. Reports Increased Revenue and Strategic Shifts in Q3 2024

Elevai Labs Inc. saw a significant increase in revenue and gross profit in the third quarter of 2024, alongside strategic changes in management and operations.

Summary

• Elevai Labs Inc. reported a revenue of $1,747,570 for the nine months ended September 30, 2024, compared to $1,014,004 for the same period in 2023.
• The company's gross profit increased to $1,278,807 from $672,882 year-over-year, with a gross profit margin of 73% in 2024 compared to 66% in 2023.
• Operating expenses totaled $5,290,718 for the nine months ended September 30, 2024, up from $3,358,152 in the prior year.
• The net loss for the nine months ended September 30, 2024, was $4,310,998, compared to a net loss of $3,143,601 for the same period in 2023.
• Elevai Labs Inc. has a net working capital of $6,097,404 as of September 30, 2024, compared to $3,622,091 as of December 31, 2023.
• The company's cash balance increased to $6,425,670 as of September 30, 2024, from $3,326,851 at the end of 2023.
• The company issued 28,571,425 shares of common stock and pre-funded warrants, raising $7,045,000 in equity.
• The company also issued notes with an aggregate principal amount of $1,150,000, which were subsequently repaid in September 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue and gross profit have increased, the company is still operating at a significant net loss and has high operating expenses. The company has also made strategic changes in management and operations, which could be positive or negative depending on their execution. The company's ability to continue as a going concern is dependent on raising additional capital and achieving profitability, which introduces uncertainty.

Positives

• The company experienced a substantial increase in revenue and gross profit, indicating strong sales growth and improved operational efficiency.
• The company's cash position has improved significantly, providing more financial flexibility.
• The company successfully raised capital through the issuance of common stock and warrants.
• The acquisition of new licenses expands the company's product portfolio and future growth potential.
• The company has seen a 92% increase in Enfinity sales volume year-over-year.

Negatives

• The company continues to operate at a net loss, with a loss of $4,310,998 for the nine months ended September 30, 2024.
• Operating expenses have increased significantly, particularly in marketing and promotion.
• The company has incurred significant consulting fees, totaling $817,030 for the nine months ended September 30, 2024.
• The company has experienced a decrease in Empower sales volume in the three months ended September 30, 2024, compared to the same period in 2023.
• The company has a history of losses and may not be able to achieve profitability.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital and achieving profitable operations.
• The company is subject to risks related to the competitive environment, changing market needs, and the ability to keep pace with new technology.
• The company is dependent on certain key personnel and may face challenges in retaining and attracting qualified personnel.
• The company faces risks related to intellectual property rights, supply chain disruptions, and government regulations.
• The company has a history of losses and may not be able to achieve profitability.
• The company is subject to the risk of not being able to maintain its listing on the Nasdaq Capital Market.

Future Outlook

The company plans to focus on growing revenue, utilizing clinical validation studies, research and development, clinical development, pursuing acquisitions, and potentially spinning off one of its subsidiaries.

Management Comments

• Management plans to grow revenue using existing infrastructure to accelerate the development and commercialization of existing and new products.
• Management intends to utilize clinical validation studies to show the effectiveness of their products.
• Management plans to pursue additional acquisitions of operating companies and/or biotechnology assets.
• Management is considering and potentially pursuing spin-offs of one of their wholly owned subsidiaries.

Industry Context

The company operates in the medical aesthetics and biopharmaceutical sectors, which are experiencing growth and innovation. The company's focus on skincare products and engineered probiotics aligns with current market trends.

Comparison to Industry Standards

• Elevai's gross profit margin of 73% for the nine months ended September 30, 2024, is relatively strong compared to some cosmetic companies, but it is important to compare it to similar companies in the medical aesthetics and biopharmaceutical sectors.
• The company's increase in marketing and promotion expenses is typical for companies in the growth phase, but it is important to monitor the return on investment.
• The company's net loss is not uncommon for early-stage biotech companies, but it is important to track the company's progress towards profitability.
• The company's cash position is relatively strong, but it is important to monitor the company's cash burn rate and its ability to raise additional capital if needed.
• The company's acquisition of new licenses is a positive sign, but it is important to assess the potential of these products and the company's ability to commercialize them successfully.

Management Changes

Corporate Governance

Legal Proceedings

• The company has voluntarily stopped sale of its products in Canada following a communication from Health Canada regarding the way the company's products are marketed in Canada.
• The company is working with Canadian regulatory and legal counsel to explore options to rectify the issues raised.

Related Party Transactions

• The company incurred consulting fees of $150,833 to GB Capital Ltd., a company controlled by Graydon Bensler, CEO, CFO and Director.
• The company incurred consulting fees of $111,100 to Northstrive Companies Inc., a company controlled by Braeden Litchi, the company's Chairman.
• The company drew $200,000 on a line of credit provided by a company controlled by Braeden Lichti during the nine months ended September 30, 2024.
• The company had $22,217 due to companies controlled by Braeden Lichti as of September 30, 2024.
• The company owed Jordan Plews, Director, $60,539 in accrued salaries as of September 30, 2024.

Stakeholder Impact

• Shareholders may be impacted by the company's net losses and the need for additional capital raises.
• Employees may be impacted by the company's restructuring and job eliminations.
• Customers may be impacted by the company's product availability and marketing strategies.
• Suppliers may be impacted by the company's purchasing decisions and supply chain management.
• Creditors may be impacted by the company's ability to repay its debts.

Next Steps

• The company intends to focus on growing revenue, utilizing clinical validation studies, research and development, clinical development, pursuing acquisitions, and potentially spinning off one of its subsidiaries.
• The company is obligated to file, prosecute and maintain intellectual property rights associated with the Licensed Products, and any improvements thereto.
• The company is working with Canadian regulatory and legal counsel to explore options to rectify the issues raised by Health Canada.

Key Dates

Keywords

skincare, biotechnology, medical aesthetics, revenue, gross profit, operating expenses, net loss, capital raise, licensing, stem cells, exosomes, warrants, probiotics